| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -2.6 | -2.0 |
| EPS (diluted, $ a share) | $-0.49 | $-1.23 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ACXP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Acurx Pharmaceuticals, Inc.: key numbers
- Share price
- $0.9350Close, Nov 16
- Market cap
- $5.66M
- Shares outstanding
- 6.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acurx Pharmaceuticals, Inc.
All →Acurx Pharmaceuticals Leadership Change
Joseph C. Scodari, a member of the Board of Directors since 2021, notified Acurx Pharmaceuticals of his intention to retire from the Board effective November 13, 2026. His departure is not due to any disagreement with the company, and he has agreed to continue serving as a corporate advisor following his retirement.
Acurx Pharmaceuticals Shareholder Meeting
Acurx Pharmaceuticals held its Annual Meeting of Stockholders on October 16, 2026, where shareholders elected David P. Luci and Jack H. Dean as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.